A selective non-peptide endothelin A (ET A ) receptor antagonist, CI-1020, was administered to cynomolgus monkeys intravenously (iv) for 2 or 4 wk and orally for 4 wk. Groups consisting of 3 animals of each sex received CI-1020 at 1, 5, and 10 mg/kg/hr (iv) or orally at 250, 500, and 750 mg/kg body weight for 4 wk. Control animals received the vehicle only. In a separate experiment, 1 male was infused with 10 mg/kg/hr for 2 wk, and Monastral blue dye was administered iv to facilitate localization of lesions to the vascular walls. One female was administered saline and the dye and served as a control. One female at 1 mg/kg/hr was found dead at week 2, and 1 female at 5 mg/kg/hr was euthanatized during week 4 as a result of severe thigh swelling at the catheter site. Macroscopically, extramural coronary arteries appeared thickened and nodular in the 4-wk iv study in the female found dead at 1 mg/kg/hr, in 1 male and 1 female at 5 mg/kg/hr, and in 2 females at 10 mg/kg/hr. Histologically, Monastral blue pigment trapped in the walls of coronary arteries with arteriopathy was observed in the male treated with CI-1020 at 10 mg/kg/hr for 2 wk. Extramural coronary arteriopathy occurred at all doses in the 4-wk iv study, with higher incidence occurring in females than in males (7 of 9 treated females compared with 3 of 9 treated males). In the oral study, 1 female at 500 mg/kg/day and 1 male and 2 females at 750 mg/kg/day had coronary arteriopathy. Histological changes after 2 wk of treatment were characterized by intimal thickening, fragmentation of the internal elastic lamina, necrosis and edema of the media, and mixed inflammatory-cell infiltrates in the intima, media, and adventitia. After 4 wk of iv administration, arteriopathy was characterized by segmental disruption of the elastic lamina and intimal and medial fibrosis with complete replacement of smooth muscle with fibrous tissue. The adventitia was thickened as a result of fibrosis and mixed or mononuclear inflammatory-cell infiltrates. CI-1020 concentrations were higher in males (1.57 to 29 &mu;g/ml) than in females (0.974 to 24.4 &mu;g/ml) in the iv study. Transient systemic exposure with high maximum plasma concentration (Cmax) (120-352 &mu;g/ml) in the oral study was insufficient to provoke arterial changes of the same magnitude as those noted with continuous iv administration. The regeneration of the media by fibrous tissue and the disruption of the elastic lamina may weaken the arterial wall and increase the susceptibility of the artery to the development of aneurysm.
INTRODUCTION
Arteriopathy (primarily in dogs) is a serious complicating factor in toxicity studies involving vasoactive compounds. Administration of various types of xenobiotics, such as vasodilators (minoxidil, theobromine, hydrazine, and type III phosphodiesterase inhibitors), and adrenergic inotropic amines (isoproterenol, norepinephrine, dopamine, and dobutamine) are associated with arteriopathy in dogs (2, 4, 7, 9, 18, 20, 25) . None of these compounds have previously been reported to induce arterial changes in monkeys; however, an adenosine agonist (CI-947) does induce coronary arteriopathy in both dogs and monkeys (1) . With CI-947, arteriopathy is seen at a higher incidence in dogs than in monkeys at comparable exposure levels.
Endothelin (ET)-l is considered the most potent vasoconstrictor discovered to date (23) . There are 2 additional related peptides, ET-2 and ET-3, and 2 distinct ETreceptor subtypes, ETA (selective for ET 1 ) and ET, (nonselective with respect to isopeptides of the ET family).
ET, receptors are abundant in cardiovascular tissue, while ETB receptors are abundant in noncardiovascular tissues, including kidney, adrenal, and central nervous system tissues (8, 23, 26) . CI-1020 (PD 156707), sodium 2-benzo [ 1, 3] dioxol-5-yl-4-(4-methoxy-phenyl)-4-oxo-3-(3,4,5-trimethoxy-benzyl)-but-2-enoate, a highly potent and selective non-peptide ET, receptor antagonist in vivo and in vitro, (24) has been investigated for use as a potential treatment option for pulmonary hypertension (5) . CI-1020 binds to human ET, receptors with an affinity that is approximately 800-fold higher than that with which it binds to human ETB receptors, as observed in competition binding assays with recombinant human ET, receptors and ET, receptors (24) .
Four-day continuous intravenous (iv) toxicity studies with CI-1020 have been conducted in dogs and monkeys. Arteriopathy was observed in dogs at doses between 0.3 and 20 mg/kg/hr (27) ; however, no arteriopathy was noted in monkeys at doses between 1 and 20 mg/kg/hr (Parke-Davis Research Institute, unpublished observations). The absence of arteriopathy in the 4-day iv study in monkeys led to subsequent 4-wk continuous iv and oral toxicity studies. These studies were conducted to provide comparative data on the toxicity of CI-1020 in nonrodent species. In this report, we describe the arterial lesions in monkeys given CI-1020 for 2 or 4 wk. To the best of our knowledge, this is the first published information on ET antagonist-induced arteriopathy in monkeys.
MATERIALS AND METHODS
Animals and Husbandry. Male and female cynomolgus monkeys, Macaca fascicularis (Primate Products, Redwood City, CA, or Charles River BRF, Inc., Houston, TX), were housed individually in a room with temperature and relative humidity maintained at 22 -~-4°C and 30-70%, respectively, and with a 12-hr light:dark cycle. The animals were provided with water ad libitum and with standard diet once daily (Purina Primate Chow 5048, Ralston Purina, Inc., St. Louis, MO); this diet was supplemented with fresh fruit at least 3 times weekly. The monkeys were cared for according to the guidelines of the Canadian Council on Animal Care and the Animals for Research Act of Ontario in a facility certified and registered under that Act.
Compound Formulation and Administration. For the iv studies, CI-1020 was dissolved in L-lysine (2 mol of L-lysine/mol of CI-1020) and 0.45% saline and administered to the animals using infusion pumps. Two weeks prior to initiation of dosing, animals were implanted with vascular access ports (VAP) and catheters using sterile surgical techniques. Surgical sites were the lateral dorsal thorax for the VAP and the upper inner thigh for catheter insertion into the femoral vein. For the oral study, CI-1020 was suspended in 0.5% aqueous methylcellulose and administered to the animals via a nasogastric tube.
Intravenous Studies. Two studies were performed. In the first study, 3 groups consisting of 3 animals of each sex received CI-1020 at 1, 5, and 10 mg/kg/hr (24, 120, 240 mg/kg/day) continuously for 4 wk at a rate of 2 ml/ kg/hr. Controls groups, consisting of 3 animals of each sex, received the vehicle only. In order to better characterize early coronary arterial lesions and to grossly localize sites of coronary vascular damage by the injection of a marker dye (Monastral blue B), a second iv investigative study was conducted. A male was administered CI-1020 at 10 mg/kg/hr (240 mg/kg/day) continuously for 2 wk at a rate of 2 ml/kg/hr. The female was not treated and served as a control. On days 11 and 12, both animals received a single bolus iv injection of 3% (w/v) suspension of Monastral blue B (Sigma-Aldrich Canada, Ltd., Oakville, Ontario, Canada) at a volume of 2 ml/kg. The vehicle for Monastral blue B was 40% hydroxypropyl-(3-cyclodextrin (Cerestar USA, Inc., Hammond, IN).
Oral Study. Three groups, consisting of 3 animals of each sex, received CI-1020 daily via a nasogastric tube at 250, 500, and 750 mg/kg body weight for 4 wk. Controls groups, consisting of 3 animals of each sex, received the vehicle only. Clinical Observations. Animals were observed for clinical signs of toxicity and for systemic effects. Food consumption was assessed daily. Monkeys were weighed prior to the initiation of the study, weekly, and again at sacrifice. Clinical and ophthalmic examinations were performed pretest and during week 4. Blood pressure and/ or electrocardiograms were done predose, after 14 days of dosing (4-wk iv study only), and within approximately 1 hr of the end of iv infusion or 2 hr after oral dosing during week 4 for iv and oral studies, respectively. Clinical Laboratory Analyses. Blood was collected from each fasted monkey pretest, on day 5 (2-wk study), during week 2 (4-wk studies), and at sacrifice. Clinical pathology parameters evaluated in blood or serum included red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, platelet count, white blood cell count (total and differential), prothrombin and activated partial thromboplastin times, urea nitrogen (BUN), creatinine, sodium, potassium, chloride, calcium, phosphorus, alanine and aspartate aminotransferase (ALT, AST), total bilirubin, alkaline phosphatase (AP), glucose, cholesterol, triglyceride, total protein, albumin, globulin, gamma glutamyl transferase, lactate dehydrogenase (total), and creatine kinase (CK). Urinalysis included evaluation of specific gravity, pH, protein, bilirubin, glucose, occult blood, ketones, urobilinogen, and microscopic evaluation. Bone marrow was taken from all monkeys at termination and was evaluated by flow cytometry and light microscopy.
Plasma CI-1020 Determinations. Heparinized blood samples were collected pretest, after 14 days of dosing, and immediately prior to termination in the 4-wk intravenous study. No samples were collected in the 2-wk study. Heparinized blood samples were collected predose and at 30 min, at 2, 4, 6, and 24 hr postdose on the first day of dosing, and during week 4 in the oral study.
Pathology. Monkeys were euthanatized with iv overdose of sodium pentobarbital. At necropsy, adrenals, brain, epididymides, heart, kidneys, liver, lung, mandibular salivary glands, ovaries, pituitary, prostate, spleen, testes, thymus, thyroid/parathyroid, and uterus (including cervix) were weighed in the 4-wk studies only. Organ: body and organ:brain weight ratios were calculated. Complete necropsies were performed on all monkeys. Samples of the following were fixed in 10% buffered formalin (except as noted), embedded in paraffin, sectioned at 4 lim, and stained with hematoxylin and eosin: brain, spinal cord, pituitary, salivary gland, thyroid, trachea, lungs and bronchi, aorta, thymus, esophagus, stomach, small intestine, large intestine, liver, gallbladder, pancreas, spleen, kidney, adrenals, urinary bladder, ovaries, testes, epididymis (the latter 2 were fixed in Bouin's fixative), uterus, vagina, prostate, mesenteric lymph node, eye (fixed in 6% buffered glutaraldehyde fixative), skeletal muscle, skin, mammary gland, sciatic nerve, bone, bone marrow, and gross lesions. In order to provide optimal fixation of the heart and the coronary vessels, the heart was removed along with a 3-5-cm segment of attached aorta. The heart was perfused-fixed ex vivo. The aorta was cannulated and perfused with Ringer's solution for 1-2 min; this was followed by perfusion with 10% buffered formalin fixative for an additional 5-10 min. In addition, 3 samples each from the circumflex branch, left interventricular, and right coronary arteries were also collected. All heart sections were also stained with Masson's trichrome (3) . For the iv studies, all of the above tissues were examined microscopically. For the oral study, only the heart, coronary arteries, and epididymis were examined microscopically.
Immunohistochemistry. Localization of actin in representative heart sections from the 4-wk iv study was performed using mouse anti-human muscle actin antibodies (clone HH35, DAKO Corp., Santa Barbara, CA). Reactions were visualized with an avidin-biotin-alkaline phosphatase kit (Vectastain ABC-AP kit, Vector Laboratories, Inc., Burlingame, CA) using Vector Red as the chromogen (Vector Laboratories). The sections were counterstained with Verhoeff hematoxylin (3) .
Electron Microscopy. Portions of the formalin-fixed coronary arteries from selected animals in the iv studies were postfixed in 3% glutaraldehyde and 1°~0 osmium tetroxide. The specimens were embedded in epoxy resin, sectioned and stained with uranyl acetate and lead citrate, and examined with CM 10 Phillips transmission electron microscope at 60 kV (Phillips Electronics Ltd., Scarborough, Ontario, Canada).
RESULTS
The following includes only drug-related results; if not reported, results were comparable to concurrent or historical controls or were not considered drug related.
Clinical Observations and Electrocardiography
In the 4-wk iv study, 1 female at 1 mg/kg/hr died during week 2 following surgery for catheter reimplantation. A second female at 5 mg/kg/hr was euthanatized in moribund condition during week 4; this female displayed severe swelling of the thigh region at the catheter insertion site. Swelling was the result of leakage of the drug into the perifemoral vein tissues. Tremors were noted in 1 male at 5 mg/kg/hr and in 2 males at 10 mg/kg/hr. Diarrhea was also noted; it was evident during the study in animals receiving 10 mg/kg/hr. No effects were apparent on electrocardiographic parameters with either route of administration.
Pathology
Except for arterial changes, no other treatment-related changes were identified. In the 2-wk study, fine blue pigmentation was noted in a descending branch of the right coronary artery and in the interventricular coronary ar-tery of the male given CI-1020. In the 4-wk iv study, CI-1020 treatment-related gross changes were noted in the extramural coronary arteries of 5 animals (the female found dead at 1 mg/kg/hr, 1 male and the moribund female at 5 mg/kg/hr, and 2 females at 10 mg/kg/hr). The lesions were seen along the interventricular coronary arteries and descending branches of the circumflex and right coronary arteries (Fig. 1 ). The lesions were characterized by multifocal nodular or diffuse thickening of the affected arteries. No dose response was noted based on incidence and severity of the pathological findings.
Histologically, in the 2-wk study the vascular changes in the treated male were acute, mild, and were characterized by intimal thickening, fragmentation of the elastic lamina, necrosis and edema of the medial smooth muscle, and marked mixed inflammatory-cell infiltrates in the intima, media, and adventitia. Monastral blue pigments were noted in the intima, media, and adventitia (Fig. 2 ). In the 4-wk iv study, lesions were noted microscopically in extramural coronary arteries of 2 males and 7 females.
Additionally, lesions in epididymal arteries of 2 males, one at 5 and one at 10 mg/kg/hr, were also noted. Arteriopathy was noted at all doses in females and at 5 and 10 mg/kg/hr in males (Table I) . Lesions were located primarily in the extramural circumflex and right coronary arteries and to a lesser extent in the extramural interventricular coronary arteries (Table  I) . Lesion severity was dose independent, and there was wide variation in lesion severity and chronicity between animals and within the same animal. Acute mild arterial changes were characterized by lifting of the endothelium secondary to intimal edema and mixed inflammatory-cell infiltrates (Fig. 3) . A few medial smooth-muscle cells were necrotic, and mixed inflammatory cells, neutrophils, eosinophils, and macrophages were seen in the media and adventitia. More severe acute lesions were noted in coronary arteries of the female found at week 2, and these lesions were characterized by large segments of medial necrosis with marked medial and adventitial neutrophilic infiltrates (Fig. 4 ). Inflammation and edema extended into the perivascular areas of the coronary groove. The intima was markedly thickened as a result of inflammation, and the elastic lamina was fragmented. Chronic active lesions were characterized by intimal thickening secondary to loose connective tissue proliferation, medial segmental fibrosis and inflammation, and marked adventitial granulation tissue formation and mixed inflammatory cell infiltrates (Fig. 5 ). Changes in chronic arteriopathy were similar to those noted in chronic active, except for the reduction of inflammatory-cell infiltrates, although lymphocytes and plasma cells were present in perivascular areas. Results from trichrome staining and the actin immunostaining of affected arteries indicated that smooth muscle cells in the media were partially or completely destroyed by the inflammatory process. In acute stages of arteriopathy, only a few smooth muscle cells were noted in the affected segment(s) of the coronary artery. In chronic lesions, the affected media was completely replaced by fibroblasts (Fig. 6 ), indicating that no regeneration of medial smooth muscle occurred, despite an absence of active inflammation. Ultrastructurally, endothelial cells in the 2-wk iv study were cuboidal and displayed clusters of apical blebbing (Fig. 7) . In severe acute lesions, necrosis of the endothelium was noted in addition to necrosis and inflammation of the media. Other changes were similar to those noted during light microscopy.
In the oral study, coronary arteriopathy was noted in 1 male at 750 mg/kg, in 1 female at 500 mg/kg, and in 2 females at 750 mg/kg. Lesions were minimal to mild and varied from acute to chronic active. There were fewer coronary arteries involved than in the 4-wk iv study. Arterial lesions were similar to those noted in the iv study, except that there were significant mononuclear cell infiltrates, macrophages, and lymphocytes in the adventitia and perivascular tissue of affected arteries in the oral study.
Plasma Drug Concentrations
Mean plasma concentrations following 14 and 28 days of continuous infusion of CI-1020 are summarized in Table II. Greater than proportional increases in plasma CI-1020 with dose were evident in both male and female monkeys following 14 days of infusion; however, this trend diminished after 28 days of infusion. Additionally, plasma CI-1020 concentrations appeared higher in males than in females, especially at day 28. With the exception of the highest dose group (10 mg/kg/hr), individual animal plasma concentrations tended to be higher at day 28 than at day 14. For the oral study, mean maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 24 hr (AUC [0-24]) values are summarized in Table III . On day 1, mean Cmax values increased proportional to dose for males but at a rate that was less than proportional to dose for females. Neither day 1 nor week 4 AUC (0-24) values increased with dose in female monkeys. AUC (0-24) values on day 1 in male monkeys increased more than proportional to dose. However, this trend was not true in males on week 4. In general, plasma CI-1020 Cmax and AUC (0-24) values were lower in week 4 than on day 1 in both sexes.
DISCUSSION
Coronary arterial lesions in the 4-wk iv study were characterized by fragmentation and/or loss of the internal elastic lamina and replacement of medial smooth muscle by fibrous connective tissue. The regeneration of the media by fibrous tissue and disruption of the internal elastic lamina may weaken the arterial wall and increase the susceptibility of the artery to development of aneurysm. Aneurysm may develop secondary to degenerative changes of the internal elastic lamina and the medial layers, augmented by hypertension (14, 15) . In addition, coronary aneurysm has been reported as a sequelae to coronary vasculitis in Kawasaki disease in children (16, 22) . More severe lesions and higher incidence of arteriopathy were noted after continuous iv administration of CI-1020 than after oral administration. Despite the high Cmax and the relatively long half-life (3.8-6 hr) of CI-1020 in monkeys, transient systemic exposure in the oral study appeared insufficient to provoke arterial changes of the same magnitude as those noted with iv administration. Similarly, bolus iv injection of up to 180 mg/kg in an iv rising-dose study in 2 monkeys (Parke-Davis Research Institute, unpublished results) did not induce vas- -Electron micrograph of cuboidal endothelial cells from the right coronary artery of a male monkey treated with CI-1020 (iv) at 10 mg/ kg/hr for 2 wk. Note the apical blebbing. Bar = 1 ~,m. cular damage. These findings were similar to those of a previous report (6) , which indicated that UK-61260 (PDE III inhibitor) induced arteriopathy in rats only after continuous iv infusion.
In both the iv and oral studies, the incidence of arteriopathy was higher in females than in males, despite higher plasma drug levels in males at all doses in the iv study and at the high dose (750 mg/kg) in the oral study. The reason for female susceptibility to arteriopathy is unknown.
The pathogenesis of endothelin antagonist-induced arterial lesions in monkeys is unknown. Previous investigations on the pathogenesis of arterial lesions induced by vasoactive compounds were performed in rats and/or dogs (2, (10) (11) (12) (13) (19) (20) (21) . These 2 species are susceptible to hemodynamic changes produced by the suprapharmacologic doses of these drugs. There is evidence that vascular injury is the result of profound and long-lasting vasodilation and the consequent increase in blood flow following administration of high doses of these compounds. Increased blood flow and vasodilation increase medial wall tension and endothelial permeability, resulting in focal subintimal/medial necrosis and hemorrhage with progression to transmural medial necrosis, hemorrhage, and inflammation (2, 11) .
It is now recognized that endothelium plays an important role in the development of vascular injury in animals and humans (11, 17) . Endothelial cells control vascular tone through the regulation of vascular wall contractility and relaxation. Endothelium is capable of synthesizing a number of vasoactive substances, both vasoconstrictors (such as thromboxanes and endothelin) and vasodilators (such as prostacyclin and nitric oxides). For this reason, alteration of endothelium may result in metabolic and TABLE II.-Plasma CI-1020 levels (jjbg/ml) in monkeys following continuous iv infusion.
Abbreviation: ND = not determined. TABLE III.-Plasma CI-1020 levels (f.Lg/ml) AUC (jjLg-hr/mI) in monkeys following oral administration.
Abbreviation: ND = not determined. biologic disorders that lead to pathologic changes (17) . Administration of high doses of an endothelin antagonist may alter the balance between relaxing and constricting factors, resulting in changes in permeability and, subsequently, in medial damage.
The cause of female death at week 2 was potentially associated with the severe coronary changes that compromised the recovery of this animal from anesthesia. The coronary changes in monkeys after 2 wk of treatment were the earliest noted with this compound. A previous 4-day continuous iv infusion of CI-1020 in monkeys at similar doses did not induce arterial changes (Parke-Davis Research Institute, unpublished results). This delayed onset of arteriopathy would suggest that the monkey is less sensitive to the development of arteriopathy than is the dog. Previous reports (10, 21) showed that dogs develop arterial changes as early as 24 hr after the administration of various vasoactive compounds. In addition, toxicity studies using this compound in dogs showed that coronary arterial changes were seen 24 hr after continuous iv infusion at lower doses (Parke-Davis Pharmaceutical Research Division, unpublished results).
Administration of endothelin antagonist (CI-1020) to monkeys for 2-4 wk caused acute to chronic coronary arteriopathy. Acute arteriopathy was characterized by medial necrosis with mixed inflammatory infiltrates in the intima, media, and adventitia, while chronic arteriopathy was characterized by replacement of medial smooth muscle cells with fibrous connective tissue.
